Innovation Pharmaceuticals Inc (IPIX)

[slcimmuno]

on valuation/deal-making... i tend to side w BK on this... Big Rx is looking for deals, and willing to pay -- handsomely even -- for early stage products/technologies, whether via licensing, a fuller partnership, even acquisition.

one example i keep going back to is the recent Merck/NGM deal. described by Forbes as "bold move" (see links below). the little guy "who brought the gold" (able to negotiate from a seat of power) struck quite a sweet deal.

CTIX seems to be setting itself up similarly. i feel v comfortable that the HDP-Ms will translate across indications (piggybacking on B), esp as safety has been established (outside of numbness/tingling... fewer AEs than Dapto) not to mention impressive efficacy shown (the beauty of mimicking the natural immune system, improving on/perfecting what Mother Nature has already been so good at: fighting off infections)... then there is that 1 day vs 7 day advantage right now for ABSSSI (but one can assume similar savings likely will extend to other treatments given MOA). and oh yeah, ABX resistance developing is less likely maybe even futile.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=111223232

that Kevetrin seems to have been granted some of the spotlight at ASCO also bodes v well.

any progress w/prurisol---bonus.

but with all that said: yes. one never knows. each to her own as to risk tolerance. leo's update obv will help inform us all as to mgmt's thinking and future direction.

FORBES
http://www.forbes.com/sites/greatspeculations/2015/03/03/mercks-partnership-with-ngm-is-a-bold-move/
EXCERPT: Last week Merck signed a deal with NGM Biopharmaceuticals, which we believe is a bold and a long-term move. Under the multi-year agreement, Merck will make a payment of $95 million to NGM to establish a co-development alliance and acquire another 15% equity stake for another $106 million. The company also offered $250 million of additional funding for any new drugs that the biopharma firm develops going forward. The deal gives a lot of flexibility and room for taking risk to NGM. It is a bold move considering there is only one disclosed compound in pre-clinical stage by NGM and it seems that Merck is essentially paying a premium to acquire its team of researchers and scientists.

WSJ
http://blogs.wsj.com/pharmalot/2015/02/24/we-had-a-bird-in-the-hand-but-ngm-chose-merck-rieflin-explains/
EXCERPT: You’re familiar with the golden rule? He who brings the gold, makes the rule. In this case, Merck is trying, in essence, not to stifle this innovative culture without being too prescriptive or officious about what we should be working on. I think this distinguishes the deal from these contract research-type deals where the big company tells the little company what to work on. We can lead R&D up to proof of concept. And after proof of concept, Merck has the ability to exercise an option to license that program. So at that point, they would run it… We have the latitude to move into other therapeutic areas.

btw, thx NR for posting the Leo email and KMBJN on the p53 MDM2-MDMX insight/summary--i still feel like im in grade school as to the science but im trying. input from folks like you is invaluable.

since we're on the deal-making/valuation topic, a few past posts of mine that might be of interest.

Biotech and Big Pharma Data
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110597458

Aggregate Data on Pharma Licensing Deals
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110986620

Brilacidin ABSSSI Approval Odds
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110335346

Brilacidin Valuation
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110042443